MedTrace Logo

Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker

NCT06098209 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-14

No results posted yet for this study

Summary

The aim of this study is to compare the efficacy of dexmedetomidine and propofol on decreasing stress in mechanically ventilated patients by using salivary alpha-amylase as a stress marker.

Conditions

  • Dexmedetomidine
  • Propofol
  • Mechanical Ventilation
  • Salivary Alpha Amylase
  • Stress

Interventions

DRUG

Dexmedetomidine

Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.

DRUG

Propofol

Patient will receive propofol 0.3-4 mg/kg/h.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2024-04-11
Completion
2024-04-11

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06098209 on ClinicalTrials.gov